Status:

COMPLETED

Analysis of Blood-based Biomarkers of Asthma

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Genentech, Inc.

Conditions:

Asthma

Eligibility:

All Genders

18-70 years

Brief Summary

The purpose of this study is to analyze markers of inflammation in blood and in induced sputum for the purpose of identifying molecular markers of specific asthma phenotypes. The investigators' specif...

Detailed Description

This is a cross-sectional study in patients with asthma and healthy controls in which we will analyze markers of inflammation in blood and in induced sputum for the purpose of identifying molecular ma...

Eligibility Criteria

Inclusion

  • Asthmatic Subjects Inclusion criteria
  • Male and female subjects between the ages of 18 and 70 years with a history of asthma who may or may not be taking inhaled corticosteroids for asthma control.
  • Physician diagnosis of asthma
  • PC20FEV1 methacholine ≤ 8.0 mg/mL, except for those taking daily inhaled corticosteroids, for which the PC20 methacholine should be \< 16 mg/mL.
  • Ability to provide informed consent.
  • Healthy Subjects Inclusion criteria
  • Healthy male and female subjects with no history of asthma between the ages of 18 and 70 years. Subjects should not be taking inhaled or oral corticosteroids.
  • No lifetime history of asthma or allergic rhinitis.
  • Ability to provide informed consent.
  • Exclusion Criteria for both subject groups
  • Lung disease other than asthma.
  • History of an upper or lower respiratory tract infection in the 4 weeks preceding the study.
  • Females who are pregnant or breast-feeding
  • Subjects must be non-smokers (patients who have never smoked or patients who have smoked ≤5 cigarettes per month and have a total pack-year smoking history \< 10 packs).
  • Use of marijuana \>1 time per month in the last year and use of marijuana in the 6 weeks prior to enrollment
  • Use of recreational drugs other than marijuana in the 12 months preceding the study.
  • Use of Beta blocker medications

Exclusion

    Key Trial Info

    Start Date :

    June 1 2009

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2011

    Estimated Enrollment :

    127 Patients enrolled

    Trial Details

    Trial ID

    NCT00917787

    Start Date

    June 1 2009

    End Date

    April 1 2011

    Last Update

    August 20 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UCSF Airway Clinical Research Center

    San Francisco, California, United States, 94143-0130